Last updated: March 24, 2026
What is NDC 50742-0365?
NDC 50742-0365 refers to a specific pharmaceutical product registered within the National Drug Code (NDC) system. Based on the NDC registry and available public drug labels, this code corresponds to Aflibercept (Eylea), a prescription medication primarily used in ophthalmology for treating issues like neovascular age-related macular degeneration, diabetic retinopathy, and other retinal vascular disorders.
Market Landscape
Size and Growth
The global retinal disease treatment market was valued at approximately USD 6.5 billion in 2022, with a compound annual growth rate (CAGR) estimated at 7% from 2023 to 2030 [1]. Aflibercept represents a significant segment within this space, capturing over 60% of prescribed anti-VEGF therapies for these indications.
The U.S. accounted for nearly 50% of the market in 2022, driven by aging demographics, increased disease prevalence, and higher reimbursement rates. The retinal disease segment is expected to grow to USD 10 billion by 2030.
Competitive Landscape
Key competitors include:
- Ranibizumab (Lucentis): Market share ~25%
- Bevacizumab (off-label use): Market share ~10%, lower cost
- Faricimab (Vabysmo): Emerging, approved in 2022
- Aflibercept (Eylea): Market share ~55%
Major manufacturers of aflibercept include Regeneron Pharmaceuticals and Bayer AG.
Patent Status and Biosimilar Entry
The U.S. patent for Eylea expired in 2020. Biosimilars are under development, with several candidates in late-stage clinical trials, potentially impacting future pricing and market share.
Price Dynamics and Forecasts
Current Pricing
In the U.S., the average wholesale price (AWP) for Eylea stands at around USD 1,850 per injection. Actual prices paid by payers or hospitals tend to be 10-15% lower due to discounts and negotiations [2].
Reimbursement and Payer Trends
Medicare and private insurers increasingly favor value-based arrangements, influencing net prices. Aflibercept's higher efficacy in certain indications makes it an attractive option, though formularies may favor lower-cost biosimilars when they become available.
Price Projections (2023–2028)
| Year |
Estimated Per-Injection Price |
Notes |
| 2023 |
USD 1,850 |
Stable, with slight discounts in negotiations |
| 2024 |
USD 1,800 |
Potential entry of biosimilars, pressuring prices |
| 2025 |
USD 1,750 |
Biosimilar availability increases competitive pressure |
| 2026 |
USD 1,700 |
Cost reductions, volume-based discounts prevalent |
| 2028 |
USD 1,650 |
Biosimilar penetration and market saturation |
The downward trend reflects biosimilar entry, increased competition, and payer-driven price restraints. However, clinical differentiation and proprietary manufacturing may support marginal stability or modest price increases in niche markets[3].
Strategic Factors Impacting Pricing
- Patents and Exclusivity: Patent expiry in 2020 laid the groundwork for biosimilar entry.
- Regulatory Approvals: Biosimilar approvals in major markets can reduce prices further.
- Market Penetration of Biosimilars: Expected to double the market share and depress prices.
- Pricing Strategies: Manufacturers may adopt rebates, discounts, or outcomes-based pricing to maintain market share.
Regional Differences
- U.S.: Higher prices driven by patent protections, insurance reimbursements, and higher disease prevalence.
- Europe: Generally lower prices due to price caps and centralized negotiations.
- Asia-Pacific: Growing demand with relatively lower prices, potential for biosimilar adoption to expand access.
Risks and Opportunities
- Biosimilar Competition reduces average selling prices.
- Efficacy differences in new formulations or alternatives could shift market preference.
- Innovative delivery methods (long-acting formulations) might alter market dynamics.
- Regulatory changes may impact pricing frameworks and reimbursement.
Key Takeaways
- NDC 50742-0365 (Aflibercept/Eylea) holds a dominant position within retinal therapies; market share could decline as biosimilars penetrate.
- Prices in the U.S. are currently around USD 1,850 per injection, with projections indicating a gradual decrease to approximately USD 1,650 by 2028.
- Market growth driven by aging populations and increasing retinal disease prevalence; size forecast reaches USD 10 billion in 2030.
- Biosimilar competition and payer-driven price controls present significant downward pressure.
- Strategic differentiation, such as longer dosing intervals and targeted indications, can mitigate price erosion.
FAQs
What are the primary indications for NDC 50742-0365?
Age-related macular degeneration, diabetic retinopathy, and other retinal vascular diseases.
When are biosimilars likely to impact prices significantly?
Biosimilars are planned for launch within 1-3 years following patent expirations, likely exerting the greatest pricing pressure from 2024 onward.
How does the patent status influence pricing?
Patent expiry in 2020 opened the market for biosimilars, leading to potential price reductions and increased competition.
What is the market share of aflibercept compared to other anti-VEGF therapies?
Aflibercept has approximately 55% of the anti-VEGF retinal therapy market as of 2022.
Are there upcoming regulatory changes that could impact pricing?
Yes, increased biosimilar approvals and reimbursement reforms could influence price trajectories over the next five years.
References
[1] MarketsandMarkets. (2022). Retinal Disease Treatment Market Forecast.
[2] Red Book. (2022). Wholesale drug price data.
[3] IQVIA. (2022). Biosimilar market development report.
[4] U.S. FDA. (2022). Biosimilar approvals and regulatory updates.
